Top Abstract Purchase Related
Home
>
Node
>
Subnode

Kinase inhibitors and their resistance

Togashi, Y.; Nishio, K.

Nihon Rinsho. Japanese Journal of Clinical Medicine 73(8): 1323-1329

2015

ISSN/ISBN: 0047-1852
PMID: 26281685
Document Number: 682242
Kinase cascades are involved in all stages of tumorigenesis through modulation of transformation and differentiation, cell-cycle progression, and motility. Advances in molecular targeted drug development allow the design and synthesis of inhibitors targeting cancer-associated signal transduction pathways. Potent selective inhibitors with low toxicity can benefit patients especially with several malignancies harboring an oncogenic driver addictive signal. This article evaluates information on solid tumor-related kinase signals and inhibitors, including receptor tyrosine kinase or serine/threonine kinase signals that lead to successful application in clinical settings. In addition, the resistant mechanisms to the inhibitors is summarized.

Document emailed within 1 workday
Secure & encrypted payments

Bagadi, S.; Saikia, T.; Pany, A.; Das, B. 2011: Analysis of ABL Kinase Domain Mutations Conferring Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Cases from India Clinical Laboratory 57(7-8): 619-623
Goldman, J. 2004: CML resistance to tyrosine kinase inhibitors: how is the laboratory to tell? Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology 10(3): 181-184
Xu, J.; Cao, H. 2013: Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors Zhonghua Wei Chang Wai Ke Za Zhi 16(3): 288-291
Levy, B.P.; Rao, P.; Becker, D.J.; Becker, K. 2016: Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors Oncology 30(7): 601-612
Ahmad, S.; Trepel, J.B.; Ohno, S.; Suzuki, K.; Tsuruo, T.; Glazer, R.I. 1992: Role of protein kinase C in the modulation of multidrug resistance: expression of the atypical gamma isoform of protein kinase C does not confer increased resistance to doxorubicin Molecular Pharmacology 42(6): 1004-1009
Li, P.M.; Fukazawa, H.; Mizuno, S.; Uehara, Y. 1993: Evaluation of protein kinase inhibitors in an assay system containing multiple protein kinase activities Anticancer Research 13(6a): 1957-1964
Dolfini, E.; Dasdia, T.; Perletti, G.; Romagnoni, M.; Piccinini, F. 1993: Analysis of calcium-dependent protein kinase-C isoenzymes in intrinsically resistant cloned lines of LoVo cells: reversal of resistance by kinase inhibitor 1-(5-isoquinolinylsulfonyl) 2-methylpiperazine Anticancer Research 13(4): 1123-1127
Courcambeck, J.ér.ôm.; Bouzidi, M.; Perbost, R.ég.; Jouirou, B.; Amrani, N.; Cacoub, P.; Pèpe, G.ér.; Sabatier, J.-M.; Halfon, P. 2006: Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations Antiviral Therapy 11(7): 847-855
Zhou, W.-D.; Chen, Q.-H.; Chen, Q.-X. 2010: The action of p38 MAP kinase and its inhibitors on endometriosis Yao Xue Xue Bao 45(5): 548-554
Mohri, M.; Shimokawa, H. 2003: Rho-kinase inhibitors for ischemic heart disease Nihon Rinsho. Japanese Journal of Clinical Medicine 61(Suppl 5): 874-879
Yazici, Y.; Steiger, B. 2012: Kinase inhibitors for the treatment of rheumatoid arthritis Bulletin of the Nyu Hospital for Joint Diseases 70(3): 204-207
Parang, K.; Sun, G. 2004: Design strategies for protein kinase inhibitors Current Opinion in Drug Discovery and Development 7(5): 617-629
Castoldi, R.E.; Pennella, G.; Saturno, G.S.; Grossi, P.; Brughera, M.; Venturi, M. 2007: Assessing and managing toxicities induced by kinase inhibitors Current Opinion in Drug Discovery and Development 10(1): 53-57
Yazici, Y.; Regens, A.L. 2011: Promising new treatments for rheumatoid arthritis - the kinase inhibitors Bulletin of the Nyu Hospital for Joint Diseases 69(3): 233-237
Pang, S.H.; Guo, Z.R.; Liang, X.T. 1997: Synthesis and biological activity of tyrosine protein kinase inhibitors Yao Xue Xue Bao 32(7): 515-523
Przytulska, J.; Tupikowski, K.; Bednarek-Tupikowska, G. 2014: Thyroid dysfunction in patients treated with tyrosine kinase inhibitors Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 36(211): 42-44
Reid, T-Elinor.; Fortunak, J.M.; Wutoh, A.; Simon Wang, X. 2016: Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors Current Topics in Medicinal Chemistry 16(13): 1452-1462
Pargellis, C.; Regan, J. 2003: Inhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis Current Opinion in Investigational Drugs 4(5): 566-571
Toledo, L.M.; Lydon, N.B.; Elbaum, D. 1999: The structure-based design of ATP-site directed protein kinase inhibitors Current Medicinal Chemistry 6(9): 775-805
Radzioch, D.; Varesio, L. 1988: Protein kinase C inhibitors block the activation of macrophages by IFN-beta but not by IFN-gamma Journal of Immunology 140(4): 1259-1263